Factors Affecting Discontinuation of Alendronate Treatment in Postmenopausal Japanese Women With Osteoporosis

Jun Iwamoto, Atsushi Miyata, Yoshihiro Sato, Tsuyoshi Takeda, Hideo Matsumoto

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: The main challenge to the long-term treatment of osteoporosis with bisphosphonates has been patient adherence. The purposes of this cohort study were to investigate the 3-year outcome of alendronate treatment in post-menopausal Japanese women with osteoporosis and to identify factors that contributed to the discontinuation of alendronate treatment. Methods: A total of 72 postmenopausal Japanese women with osteoporosis and aged from 58 to 85 years were treated with alendronate in a 3-year trial. Metacarpal bone mineral density, serum alkaline phosphatase, and urinary cross-linked N-terminal telopeptides of type I collagen were monitored, and factors contributing to the discontinuation of alendronate treatment were determined. Results: Fourteen patients dropped out of the trial. The reasons for dropout were side effects (diarrhea [n = 1], gastric symptoms [n = 9], and inflammation of the mouth [n = 1]) or non-compliance (n = 3). Logistic regression analysis showed that the number of prevalent vertebral fractures was a significant factor affecting the discontinuation of alendronate treatment for the reasons listed above. In 58 patients who continued the 3-year treatment, urinary cross-linked N-terminal telopeptides of type I collagen level was reduced by 44.1% at 3 months and serum alkaline phosphatase level was decreased by 11.6%, 11.8%, and 12.5% at 1, 2, and 3 years, respectively. However, metacarpal bone mineral density did not change significantly. Conclusion: Alendronate treatment decreased urinary cross-linked N-terminal telopeptides of type I collagen and serum alkaline phosphatase levels, and maintained metacarpal bone mineral density in postmenopausal Japanese women with osteoporosis. The patients adhered well to alendronate treatment in our clinic. The number of prevalent vertebral fractures was an important factor affecting the discontinuation of alendronate treatment due to side effects and non-compliance.

Original languageEnglish
Pages (from-to)619-624
Number of pages6
JournalJournal of the Chinese Medical Association
Volume72
Issue number12
DOIs
Publication statusPublished - 2009 Dec

Fingerprint

Alendronate
Osteoporosis
Metacarpal Bones
Bone Density
Alkaline Phosphatase
Therapeutics
Serum
Diphosphonates
Patient Compliance
Mouth
Diarrhea
Stomach
Cohort Studies
Logistic Models
Regression Analysis
Inflammation

Keywords

  • alendronate
  • bone mineral density
  • cross-linked N-terminal telopeptides of type I collagen
  • metacarpus
  • osteoporosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Factors Affecting Discontinuation of Alendronate Treatment in Postmenopausal Japanese Women With Osteoporosis. / Iwamoto, Jun; Miyata, Atsushi; Sato, Yoshihiro; Takeda, Tsuyoshi; Matsumoto, Hideo.

In: Journal of the Chinese Medical Association, Vol. 72, No. 12, 12.2009, p. 619-624.

Research output: Contribution to journalArticle

Iwamoto, Jun ; Miyata, Atsushi ; Sato, Yoshihiro ; Takeda, Tsuyoshi ; Matsumoto, Hideo. / Factors Affecting Discontinuation of Alendronate Treatment in Postmenopausal Japanese Women With Osteoporosis. In: Journal of the Chinese Medical Association. 2009 ; Vol. 72, No. 12. pp. 619-624.
@article{5aadfde7a7db4db8b2250df55f719820,
title = "Factors Affecting Discontinuation of Alendronate Treatment in Postmenopausal Japanese Women With Osteoporosis",
abstract = "Background: The main challenge to the long-term treatment of osteoporosis with bisphosphonates has been patient adherence. The purposes of this cohort study were to investigate the 3-year outcome of alendronate treatment in post-menopausal Japanese women with osteoporosis and to identify factors that contributed to the discontinuation of alendronate treatment. Methods: A total of 72 postmenopausal Japanese women with osteoporosis and aged from 58 to 85 years were treated with alendronate in a 3-year trial. Metacarpal bone mineral density, serum alkaline phosphatase, and urinary cross-linked N-terminal telopeptides of type I collagen were monitored, and factors contributing to the discontinuation of alendronate treatment were determined. Results: Fourteen patients dropped out of the trial. The reasons for dropout were side effects (diarrhea [n = 1], gastric symptoms [n = 9], and inflammation of the mouth [n = 1]) or non-compliance (n = 3). Logistic regression analysis showed that the number of prevalent vertebral fractures was a significant factor affecting the discontinuation of alendronate treatment for the reasons listed above. In 58 patients who continued the 3-year treatment, urinary cross-linked N-terminal telopeptides of type I collagen level was reduced by 44.1{\%} at 3 months and serum alkaline phosphatase level was decreased by 11.6{\%}, 11.8{\%}, and 12.5{\%} at 1, 2, and 3 years, respectively. However, metacarpal bone mineral density did not change significantly. Conclusion: Alendronate treatment decreased urinary cross-linked N-terminal telopeptides of type I collagen and serum alkaline phosphatase levels, and maintained metacarpal bone mineral density in postmenopausal Japanese women with osteoporosis. The patients adhered well to alendronate treatment in our clinic. The number of prevalent vertebral fractures was an important factor affecting the discontinuation of alendronate treatment due to side effects and non-compliance.",
keywords = "alendronate, bone mineral density, cross-linked N-terminal telopeptides of type I collagen, metacarpus, osteoporosis",
author = "Jun Iwamoto and Atsushi Miyata and Yoshihiro Sato and Tsuyoshi Takeda and Hideo Matsumoto",
year = "2009",
month = "12",
doi = "10.1016/S1726-4901(09)70442-3",
language = "English",
volume = "72",
pages = "619--624",
journal = "Journal of the Chinese Medical Association",
issn = "1726-4901",
publisher = "Elsevier Taiwan LLC",
number = "12",

}

TY - JOUR

T1 - Factors Affecting Discontinuation of Alendronate Treatment in Postmenopausal Japanese Women With Osteoporosis

AU - Iwamoto, Jun

AU - Miyata, Atsushi

AU - Sato, Yoshihiro

AU - Takeda, Tsuyoshi

AU - Matsumoto, Hideo

PY - 2009/12

Y1 - 2009/12

N2 - Background: The main challenge to the long-term treatment of osteoporosis with bisphosphonates has been patient adherence. The purposes of this cohort study were to investigate the 3-year outcome of alendronate treatment in post-menopausal Japanese women with osteoporosis and to identify factors that contributed to the discontinuation of alendronate treatment. Methods: A total of 72 postmenopausal Japanese women with osteoporosis and aged from 58 to 85 years were treated with alendronate in a 3-year trial. Metacarpal bone mineral density, serum alkaline phosphatase, and urinary cross-linked N-terminal telopeptides of type I collagen were monitored, and factors contributing to the discontinuation of alendronate treatment were determined. Results: Fourteen patients dropped out of the trial. The reasons for dropout were side effects (diarrhea [n = 1], gastric symptoms [n = 9], and inflammation of the mouth [n = 1]) or non-compliance (n = 3). Logistic regression analysis showed that the number of prevalent vertebral fractures was a significant factor affecting the discontinuation of alendronate treatment for the reasons listed above. In 58 patients who continued the 3-year treatment, urinary cross-linked N-terminal telopeptides of type I collagen level was reduced by 44.1% at 3 months and serum alkaline phosphatase level was decreased by 11.6%, 11.8%, and 12.5% at 1, 2, and 3 years, respectively. However, metacarpal bone mineral density did not change significantly. Conclusion: Alendronate treatment decreased urinary cross-linked N-terminal telopeptides of type I collagen and serum alkaline phosphatase levels, and maintained metacarpal bone mineral density in postmenopausal Japanese women with osteoporosis. The patients adhered well to alendronate treatment in our clinic. The number of prevalent vertebral fractures was an important factor affecting the discontinuation of alendronate treatment due to side effects and non-compliance.

AB - Background: The main challenge to the long-term treatment of osteoporosis with bisphosphonates has been patient adherence. The purposes of this cohort study were to investigate the 3-year outcome of alendronate treatment in post-menopausal Japanese women with osteoporosis and to identify factors that contributed to the discontinuation of alendronate treatment. Methods: A total of 72 postmenopausal Japanese women with osteoporosis and aged from 58 to 85 years were treated with alendronate in a 3-year trial. Metacarpal bone mineral density, serum alkaline phosphatase, and urinary cross-linked N-terminal telopeptides of type I collagen were monitored, and factors contributing to the discontinuation of alendronate treatment were determined. Results: Fourteen patients dropped out of the trial. The reasons for dropout were side effects (diarrhea [n = 1], gastric symptoms [n = 9], and inflammation of the mouth [n = 1]) or non-compliance (n = 3). Logistic regression analysis showed that the number of prevalent vertebral fractures was a significant factor affecting the discontinuation of alendronate treatment for the reasons listed above. In 58 patients who continued the 3-year treatment, urinary cross-linked N-terminal telopeptides of type I collagen level was reduced by 44.1% at 3 months and serum alkaline phosphatase level was decreased by 11.6%, 11.8%, and 12.5% at 1, 2, and 3 years, respectively. However, metacarpal bone mineral density did not change significantly. Conclusion: Alendronate treatment decreased urinary cross-linked N-terminal telopeptides of type I collagen and serum alkaline phosphatase levels, and maintained metacarpal bone mineral density in postmenopausal Japanese women with osteoporosis. The patients adhered well to alendronate treatment in our clinic. The number of prevalent vertebral fractures was an important factor affecting the discontinuation of alendronate treatment due to side effects and non-compliance.

KW - alendronate

KW - bone mineral density

KW - cross-linked N-terminal telopeptides of type I collagen

KW - metacarpus

KW - osteoporosis

UR - http://www.scopus.com/inward/record.url?scp=74249100169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74249100169&partnerID=8YFLogxK

U2 - 10.1016/S1726-4901(09)70442-3

DO - 10.1016/S1726-4901(09)70442-3

M3 - Article

VL - 72

SP - 619

EP - 624

JO - Journal of the Chinese Medical Association

JF - Journal of the Chinese Medical Association

SN - 1726-4901

IS - 12

ER -